| 7.2 0.02 (0.28%) | 12-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.81 | 1-year : | 10.29 |
| Resists | First : | 7.55 | Second : | 8.81 |
| Pivot price | 6.95  |
|||
| Supports | First : | 6.53 | Second : | 5.9 |
| MAs | MA(5) : | 7.11 |
MA(20) : | 6.95 |
| MA(100) : | 6.74 |
MA(250) : | 0 | |
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 67.2 |
D(3) : | 57.4 |
| RSI | RSI(14): 60 |
|||
| 52-week | High : | 8.68 | Low : | 4.25 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ BHC ] has closed below upper band by 10.5%. Bollinger Bands are 53.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 7.25 - 7.28 | 7.28 - 7.3 |
| Low: | 7.07 - 7.11 | 7.11 - 7.14 |
| Close: | 7.14 - 7.2 | 7.2 - 7.25 |
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Thu, 25 Dec 2025
What is Zacks Research's Estimate for TSE:BHC Q4 Earnings? - MarketBeat
Wed, 24 Dec 2025
Bausch Health (BHC) Is Up 5.3% After US$1.6 Billion Debt Exchange - Has The Bull Case Changed? - Yahoo Finance
Tue, 23 Dec 2025
Bausch Health announces completion of $1.6 billion debt exchange offer - Investing.com
Tue, 23 Dec 2025
Bausch Health Announces Final Results and Expiration of Exchange Offers - ACCESS Newswire
Tue, 23 Dec 2025
Bausch Health Companies Inc Announces Final Results of Exchange Offers - TradingView — Track All Markets
Mon, 22 Dec 2025
Bausch Health’s Large 2032 Debt Exchange Might Change The Case For Investing In Bausch Health (BHC) - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 371 (M) |
| Shares Float | 223 (M) |
| Held by Insiders | 10.7 (%) |
| Held by Institutions | 66.9 (%) |
| Shares Short | 5,650 (K) |
| Shares Short P.Month | 6,480 (K) |
| EPS | 0.97 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.52 |
| Profit Margin | 3.6 % |
| Operating Margin | 26.7 % |
| Return on Assets (ttm) | 4.8 % |
| Return on Equity (ttm) | 563.1 % |
| Qtrly Rev. Growth | 6.8 % |
| Gross Profit (p.s.) | 19.13 |
| Sales Per Share | 27.07 |
| EBITDA (p.s.) | 8.87 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 1,510 (M) |
| Levered Free Cash Flow | 1,240 (M) |
| PE Ratio | 7.42 |
| PEG Ratio | 0 |
| Price to Book value | -4.74 |
| Price to Sales | 0.26 |
| Price to Cash Flow | 1.76 |
| Dividend | 1 |
| Forward Dividend | 0 |
| Dividend Yield | 13.8% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|